FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362594857> ?p ?o ?g. }

• W4362594857 endingPage "6788" @default.
• W4362594857 startingPage "6788" @default.
• W4362594857 abstract "Abstract Background: CF33-hNIS-anti-PD-L1 is a novel chimeric orthopoxvirus shown to have anti-cancer activity in triple negative breast cancer (TNBC) xenografts. For clinical tracking of the oncolytic virus (OV), human sodium iodide symporter (hNIS) transgene was inserted into the virus. hNIS gene expression allows cells to take up iodine and be visible by non-invasive imaging techniques. Animal studies showed that tumor cells infected with CF33-hNIS-anti-PD-L1 express functional hNIS and are visible by single-photon emission computed tomography (SPECT) or positron emission tomography (PET). The current report describes imaging results from an ongoing first-in-human trial. Methods: This is a phase I, single center, single arm clinical trial evaluating the safety and tolerability of CF33-hNIS-anti-PD-L1 intratumoral (IT) injections in patients with metastatic TNBC. Key eligibility criteria include patients with unresectable or metastatic TNBC; progressed on at least 2 prior chemotherapies; ECOG 0-2; RECIST 1.1 measurable disease; and at least one tumor amenable to repeated IT injections. Eligible patients receive CF33-hNIS-anti-PD-L1 IT at 1 of 8 assigned dose levels (from 1 × 105 PFU to 3 x 108 PFU) on Days 1 and 15 of each 28-day cycle for a total of 3 cycles of treatment. The primary objective is to evaluate the safety and tolerability of CF33-hNIS-anti-PD-L1. Secondary objectives are to determine optimal biological dose, recommended phase II dose, and response rates. Exploratory objectives include assessing feasibility of non-invasive hNIS imaging as a method of tracking viral infection and replication. SPECT whole body imaging was performed at Cycle 1 Day 8 (C1D8). Results: From October 2021 to October 2022, 8 patients were enrolled in this ongoing study and received at least 1 dose of CF33-hNIS-anti-PD-L1 injection at one of the first 3 dose levels (1 x 105, 3 x 105, or 1 x 106 PFU). All 8 patients underwent SPECT imaging at C1D8 with 6/8 patients (75%) having uptake at the site of injection on the SPECT imaging study. Four of 4 patients (100%) with injection sites at metastatic subcutaneous nodules, intramuscular masses, or axillary lymph nodes and 2/4 patients (50%) with injection sites at matted dermal metastatic lesions had uptake on SPECT. Conclusion: SPECT imaging successfully showed enhancement at the injected lesions in 75% of patients treated with CF33-hNIS-anti-PD-L1, even at current low doses, suggesting local viral replication and hNIS expression. Further analysis will evaluate the correlation of SPECT imaging results with pathologic immune cell infiltrate, viral staining, and tumor response. This is the first known report of hNIS-based imaging to track oncolytic poxvirus replication in humans and gives promise that this technology may be used for noninvasive tracking of systemically administered OV and other therapies. Citation Format: Jamie Green Rand, Dave Yamauchi, Shyambabu Chaurasiya, Jianying Zhang, Raju Pillai, Colt Egelston, Jonathan Kessler, Badri Modi, Leslie Chong, Amanda Seiz, Giovanni Selvaggi, Nick Ede, Mireya Murga, Norma Martinez, Wichanee Borisuthirattana, Hans Meisen, Susan Yost, James Waisman, Daphne Stewart, Joanne Mortimer, Yuman Fong, Yuan Yuan. hNIS imaging data from a first-in-human trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6788." @default.
• W4362594857 created "2023-04-06" @default.
• W4362594857 creator A5004500382 @default.
• W4362594857 creator A5005344580 @default.
• W4362594857 creator A5005473474 @default.
• W4362594857 creator A5005824918 @default.
• W4362594857 creator A5011540763 @default.
• W4362594857 creator A5011883493 @default.
• W4362594857 creator A5023105695 @default.
• W4362594857 creator A5026801911 @default.
• W4362594857 creator A5028773984 @default.
• W4362594857 creator A5035852624 @default.
• W4362594857 creator A5037742105 @default.
• W4362594857 creator A5041448171 @default.
• W4362594857 creator A5050269323 @default.
• W4362594857 creator A5052270503 @default.
• W4362594857 creator A5067353931 @default.
• W4362594857 creator A5069961709 @default.
• W4362594857 creator A5071244558 @default.
• W4362594857 creator A5072747994 @default.
• W4362594857 creator A5074603645 @default.
• W4362594857 creator A5078374050 @default.
• W4362594857 creator A5079957494 @default.
• W4362594857 creator A5089657869 @default.
• W4362594857 date "2023-04-04" @default.
• W4362594857 modified "2023-10-14" @default.
• W4362594857 title "Abstract 6788: hNIS imaging data from a first-in-human trial of the oncolytic virus CF33-hNIS-antiPD-L1 in patients with triple negative breast cancer" @default.
• W4362594857 doi "https://doi.org/10.1158/1538-7445.am2023-6788" @default.
• W4362594857 hasPublicationYear "2023" @default.
• W4362594857 type Work @default.
• W4362594857 citedByCount "0" @default.
• W4362594857 crossrefType "journal-article" @default.
• W4362594857 hasAuthorship W4362594857A5004500382 @default.
• W4362594857 hasAuthorship W4362594857A5005344580 @default.
• W4362594857 hasAuthorship W4362594857A5005473474 @default.
• W4362594857 hasAuthorship W4362594857A5005824918 @default.
• W4362594857 hasAuthorship W4362594857A5011540763 @default.
• W4362594857 hasAuthorship W4362594857A5011883493 @default.
• W4362594857 hasAuthorship W4362594857A5023105695 @default.
• W4362594857 hasAuthorship W4362594857A5026801911 @default.
• W4362594857 hasAuthorship W4362594857A5028773984 @default.
• W4362594857 hasAuthorship W4362594857A5035852624 @default.
• W4362594857 hasAuthorship W4362594857A5037742105 @default.
• W4362594857 hasAuthorship W4362594857A5041448171 @default.
• W4362594857 hasAuthorship W4362594857A5050269323 @default.
• W4362594857 hasAuthorship W4362594857A5052270503 @default.
• W4362594857 hasAuthorship W4362594857A5067353931 @default.
• W4362594857 hasAuthorship W4362594857A5069961709 @default.
• W4362594857 hasAuthorship W4362594857A5071244558 @default.
• W4362594857 hasAuthorship W4362594857A5072747994 @default.
• W4362594857 hasAuthorship W4362594857A5074603645 @default.
• W4362594857 hasAuthorship W4362594857A5078374050 @default.
• W4362594857 hasAuthorship W4362594857A5079957494 @default.
• W4362594857 hasAuthorship W4362594857A5089657869 @default.
• W4362594857 hasConcept C104317684 @default.
• W4362594857 hasConcept C120405084 @default.
• W4362594857 hasConcept C121608353 @default.
• W4362594857 hasConcept C126322002 @default.
• W4362594857 hasConcept C143998085 @default.
• W4362594857 hasConcept C149011108 @default.
• W4362594857 hasConcept C185592680 @default.
• W4362594857 hasConcept C197934379 @default.
• W4362594857 hasConcept C2775930923 @default.
• W4362594857 hasConcept C2778375690 @default.
• W4362594857 hasConcept C2780110267 @default.
• W4362594857 hasConcept C2780616701 @default.
• W4362594857 hasConcept C502942594 @default.
• W4362594857 hasConcept C530470458 @default.
• W4362594857 hasConcept C55493867 @default.
• W4362594857 hasConcept C71924100 @default.
• W4362594857 hasConcept C82210918 @default.
• W4362594857 hasConceptScore W4362594857C104317684 @default.
• W4362594857 hasConceptScore W4362594857C120405084 @default.
• W4362594857 hasConceptScore W4362594857C121608353 @default.
• W4362594857 hasConceptScore W4362594857C126322002 @default.
• W4362594857 hasConceptScore W4362594857C143998085 @default.
• W4362594857 hasConceptScore W4362594857C149011108 @default.
• W4362594857 hasConceptScore W4362594857C185592680 @default.
• W4362594857 hasConceptScore W4362594857C197934379 @default.
• W4362594857 hasConceptScore W4362594857C2775930923 @default.
• W4362594857 hasConceptScore W4362594857C2778375690 @default.
• W4362594857 hasConceptScore W4362594857C2780110267 @default.
• W4362594857 hasConceptScore W4362594857C2780616701 @default.
• W4362594857 hasConceptScore W4362594857C502942594 @default.
• W4362594857 hasConceptScore W4362594857C530470458 @default.
• W4362594857 hasConceptScore W4362594857C55493867 @default.
• W4362594857 hasConceptScore W4362594857C71924100 @default.
• W4362594857 hasConceptScore W4362594857C82210918 @default.
• W4362594857 hasIssue "7_Supplement" @default.
• W4362594857 hasLocation W43625948571 @default.
• W4362594857 hasOpenAccess W4362594857 @default.
• W4362594857 hasPrimaryLocation W43625948571 @default.
• W4362594857 hasRelatedWork W144521535 @default.
• W4362594857 hasRelatedWork W1966181922 @default.
• W4362594857 hasRelatedWork W1999292713 @default.
• W4362594857 hasRelatedWork W2285340499 @default.
• W4362594857 hasRelatedWork W2317787856 @default.
• W4362594857 hasRelatedWork W2366029130 @default.

• next